AYLA Insider Trading Activity and SEC Form 4 Filings
AYLA insider trading summary
No open-market insider purchases or sales of Ayala Pharmaceuticals, Inc. (AYLA) have been reported on SEC Form 4 in the past 12 months.
Latest AYLA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 24, 2021 | Gary B. Gordon | Chief Medical Officer | Sell | $52K (3,000 @ $17.46) |
| Feb 24, 2021 | Roni Mamluk | President & CEO | Sell | $188K (10,800 @ $17.40) |
| Feb 23, 2021 | Roni Mamluk | President & CEO | Sell | $127K (7,126 @ $17.89) |
| Feb 22, 2021 | Roni Mamluk | President & CEO | Sell | $302K (15,200 @ $19.86) |
| Jan 21, 2021 | Roni Mamluk | President & CEO | Sell | $21K (1,406 @ $15.04) |
| Jan 20, 2021 | Gary B. Gordon | Chief Medical Officer | Sell | $45K (3,000 @ $15.03) |
| Jan 20, 2021 | Roni Mamluk | President & CEO | Sell | $293K (19,466 @ $15.03) |
| Dec 23, 2020 | David Sidransky | Director | Buy | $46 (4 @ $11.56) |
| Sep 14, 2020 | David Sidransky | Director | Buy | $11 (1 @ $10.70) |
| Sep 11, 2020 | David Sidransky | Director | Buy | $101 (10 @ $10.07) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.